GHRP-2, also known as pralmorelin, is a synthetic growth hormone-releasing peptide that belongs to a class of compounds designed to stimulate endogenous growth hormone secretion. Researchers primarily study GHRP-2 for its potential role in diagnosing growth hormone deficiencies and its effects on increasing serum insulin-like growth factor-1 (IGF-1) levels. Key findings from studies indicate that GHRP-2 can significantly elevate plasma growth hormone levels in healthy individuals, while its efficacy may be reduced in those with growth hormone deficiencies. Additionally, GHRP-2 has been shown to maintain its growth hormone-releasing activity across various age groups, although its effectiveness diminishes with advancing age. Current research continues to explore its applications in clinical settings, particularly in relation to growth hormone-related disorders.